Lonza announced plans to construct a large-scale commercial drug product fil and finish facility in Stein (CH). The investment will enable the company to provide customers with a complete and integrated end-to-end solution that includes commercial drug product manufacturing for large-scale market supply. The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026.

The new flexible facility will be constructed in Stein (CH) on the same campus as Lonza's current clinical drug product facility, allowing the company to leverage the existing infrastructure, capabilities and talent.